Intravesical Instillation Therapy: Alternative Treatments
The high recurrence rate of superficial bladder cancer after transurethral resection (TUR) has stimulated urologists and urological investigators to explore pathways to prevent and/or reduce recurrent tumors. For more than three decades intravesical chemotherapy has been applied, and more recently intravesical immunotherapy has also been proposed. Since 20% of recurrent tumors eventually will progress and/or cause metastases, it is obvious that these forms of intravesical treatment also aim at prevention of progression and/or metastases [1,2].
KeywordsToxicity Europe Bacillus Doxorubicin Tryptophan
Unable to display preview. Download preview PDF.
- 6.Lamm DL, Steg A, Boccon-Gibod L, Morales A, Hanna MG Jr, Pagano F, Alfthan O, Brosman S, Fisher HAF, Jakse G, Chisholm GD, van der Meijden APM, Debruyne FMJ (1989) Complications of bacillus Calmette-Guérin immunotherapy: review of 2602 patients and comparison of chemotherapy complications. In: Debruyne FMJ, Denis L, van der Meijden APM (eds) EORTC Genito-Urinary Group monograph 6: BCG in superficial bladder cancer. Liss, New York, pp 335–355Google Scholar
- 8.van der Meijden APM, Steerenberg PA, van Hoogstraten IMW, Kerckhaert JA, Schreinemachers LMH, Harthoorn-Lasthuizen EJ, Hagenaars AM, de Jong WH, Debruyne FMJ, Ruitenberg EJ (1989) Immune reactions in patients with superficial bladder cancer after intradermal and intravesical treatment with bacillus Calmette-Guérin. Cancer Immunol Immunother 28:287–295PubMedCrossRefGoogle Scholar
- 9.Brosman SA, Lamm DL, Meijden APM, et al. (1989) A practical guide to the use of intravesical BCG for the management of stage Ta, T1, CIS, transitional cell cancer. In: Debruyne FMJ, Denis L, van der Meijden APM (eds) EORTC Genito-urinary Group monograph 6: BCG in superficial bladder cancer. Liss, New York, pp 311–323Google Scholar
- 10.Parmar MKB, Freedman LS, Hargreave TB, Tolley DA (1989) Prognostic factors for recurrence and follow-up policies in the treatment of superficial bladder cancer: report from the British Medical Research Council Subgroup on Superficial Bladder Cancer (Urological Cancer Working Party). J Urol 142:284–288PubMedGoogle Scholar
- 11.Cutler SJ, Heney NM, Friedell GH (1982) Longitudinal study of patients with bladder cancer: factors associated with disease recurrence and progression. In: Bonney WW, Prout GR (eds) Bladder cancer, AUA monograph, vol 1, chap 4: Williams & Wilkins, Baltimore, pp 35–46Google Scholar
- 12.Dalesio O, Schulman CC, Sylvester R, et al. (1983) Prognostic factors in superficial bladder tumors. A study of the EORTC group, GU group, J Urol 129:730–733Google Scholar
- 23.Olumi AF, Tsai YC, Nichols PW, Skinner DG, Cain DR, Bender LI, Jones PA (1990) Allelic loss of chromosomes 17p distinguishes high grade from low grade transitional cell carcinomas of the bladder. Cancer Res 50:7061–7063Google Scholar
- 25.Brinquier PP, Schalken JA, Debruyne FMJ (1990) New markers for biological aggressiveness of bladder cancer: Proceedings of the 2nd International Symposium on recent advances in urological cancer diagnosis and treatment, 1990Google Scholar